Cargando…
The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering
Angiogenesis plays an essential role in rapid growing and metastasis of the tumors. Inhibition of angiogenesis is a putative strategy for cancer therapy. Endostatin (Es) is an attractive anti-angiogenesis protein with some clinical application challenges including; short half-life, instability in se...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tabriz University of Medical Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426730/ https://www.ncbi.nlm.nih.gov/pubmed/28507934 http://dx.doi.org/10.15171/apb.2017.004 |
_version_ | 1783235539978158080 |
---|---|
author | Mohajeri, Abbas Sanaei, Sarvin Kiafar, Farhad Fattahi, Amir Khalili, Majid Zarghami, Nosratollah |
author_facet | Mohajeri, Abbas Sanaei, Sarvin Kiafar, Farhad Fattahi, Amir Khalili, Majid Zarghami, Nosratollah |
author_sort | Mohajeri, Abbas |
collection | PubMed |
description | Angiogenesis plays an essential role in rapid growing and metastasis of the tumors. Inhibition of angiogenesis is a putative strategy for cancer therapy. Endostatin (Es) is an attractive anti-angiogenesis protein with some clinical application challenges including; short half-life, instability in serum and requirement to high dosage. Therefore, production of recombinant endostatin (rEs) is necessary in large scale. The production of rEs is difficult because of its structural properties and is high-cost. Therefore, this review focused on the different expression systems that involved in rEs production including; mammalian, baculovirus, yeast, and Escherichia coli (E. coli) expression systems. The evaluating of the results of different expression systems declared that none of the mentioned systems can be considered to be generally superior to the other. Meanwhile with considering the advantages and disadvantage of E. coli expression system compared with other systems beside the molecular properties of Es, E. coli expression system can be a preferred expression system for expressing of the Es in large scale. Also, the molecular bioengineering and sustained release formulations that lead to improving of its stability and bioactivity will be discussed. Point mutation (P125A) of Es, addition of RGD moiety or an additional zinc biding site to N-terminal of Es , fusing of Es to anti-HER2 IgG or heavy-chain of IgG, and finally loading of the endostar by PLGA and PEG- PLGA nanoparticles and gold nano-shell particles are the effective bioengineering methods to overcome to clinical changes of endostatin. |
format | Online Article Text |
id | pubmed-5426730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Tabriz University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-54267302017-05-15 The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering Mohajeri, Abbas Sanaei, Sarvin Kiafar, Farhad Fattahi, Amir Khalili, Majid Zarghami, Nosratollah Adv Pharm Bull Review Article Angiogenesis plays an essential role in rapid growing and metastasis of the tumors. Inhibition of angiogenesis is a putative strategy for cancer therapy. Endostatin (Es) is an attractive anti-angiogenesis protein with some clinical application challenges including; short half-life, instability in serum and requirement to high dosage. Therefore, production of recombinant endostatin (rEs) is necessary in large scale. The production of rEs is difficult because of its structural properties and is high-cost. Therefore, this review focused on the different expression systems that involved in rEs production including; mammalian, baculovirus, yeast, and Escherichia coli (E. coli) expression systems. The evaluating of the results of different expression systems declared that none of the mentioned systems can be considered to be generally superior to the other. Meanwhile with considering the advantages and disadvantage of E. coli expression system compared with other systems beside the molecular properties of Es, E. coli expression system can be a preferred expression system for expressing of the Es in large scale. Also, the molecular bioengineering and sustained release formulations that lead to improving of its stability and bioactivity will be discussed. Point mutation (P125A) of Es, addition of RGD moiety or an additional zinc biding site to N-terminal of Es , fusing of Es to anti-HER2 IgG or heavy-chain of IgG, and finally loading of the endostar by PLGA and PEG- PLGA nanoparticles and gold nano-shell particles are the effective bioengineering methods to overcome to clinical changes of endostatin. Tabriz University of Medical Sciences 2017-04 2017-04-13 /pmc/articles/PMC5426730/ /pubmed/28507934 http://dx.doi.org/10.15171/apb.2017.004 Text en ©2017 The Authors. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. |
spellingShingle | Review Article Mohajeri, Abbas Sanaei, Sarvin Kiafar, Farhad Fattahi, Amir Khalili, Majid Zarghami, Nosratollah The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering |
title | The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering |
title_full | The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering |
title_fullStr | The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering |
title_full_unstemmed | The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering |
title_short | The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering |
title_sort | challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426730/ https://www.ncbi.nlm.nih.gov/pubmed/28507934 http://dx.doi.org/10.15171/apb.2017.004 |
work_keys_str_mv | AT mohajeriabbas thechallengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT sanaeisarvin thechallengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT kiafarfarhad thechallengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT fattahiamir thechallengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT khalilimajid thechallengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT zarghaminosratollah thechallengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT mohajeriabbas challengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT sanaeisarvin challengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT kiafarfarhad challengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT fattahiamir challengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT khalilimajid challengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering AT zarghaminosratollah challengesofrecombinantendostatininclinicalapplicationfocusonthedifferentexpressionsystemsandmolecularbioengineering |